ARCH-backed Chi­nese biotech scores PhI­II win for glu­cok­i­nase-mod­u­lat­ing di­a­betes drug

When ARCH Ven­ture Part­ners helped launch Hua Med­i­cine with for­mer Roche ex­ec Li Chen, it marked one of the first bets on a Chi­nese biotech to de­liv­er a world-class di­a­betes drug. Eight years lat­er, their lead drug ap­pears to have turned the cor­ner and en­tered the fi­nal stretch.

Late on Mon­day night Shang­hai time — where it’s based — Hua un­veiled pos­i­tive da­ta from the first part of its piv­otal study of dorza­gli­atin, cel­e­brat­ing a win on the pri­ma­ry end­point as well as de­cent safe­ty re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA